Anovulation including polycystic ovarian disease (PCOD) in women who have been unresponsive to treatment w/ clomiphene citrate. Controlled ovarian hyperstimulation to induce development of multiple follicles for assisted reproductive technologies (ART) eg, in vitro fertilisation/embryo transfer, gamete intra-fallopian transfer & intracytoplasmic sperm inj.
SC/IMWomen w/ anovulation including PCOD Start w/in initial 7 days of menstrual cycle. Initially 75-150 IU daily, maintained for at least 7 days. May be increased in 37.5-75 IU increments up to max: 225 IU daily. Single inj of 5,000-10,000 IU hCG is given 1 day after the last inj to induce ovulation. Women undergoing controlled ovarian hyperstimulation for multiple follicular development for ART Start approx 2 wk after initiation of agonist treatment or on day 2 or 3 of menstrual cycle: Initially 150-225 IU daily for at least 1st 5 days, may be adjusted in not >150 IU increments up to max: 450 IU daily. Max duration: 20 days. Single inj of up to 10,000 IU hCG should be administered to induce follicular maturation in prep for oocyte retrieval.
View Menopur overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity. Pituitary or hypothalamic tumors; ovarian, uterine or mammary carcinoma; gynecological hemorrhage of unknown etiology; ovarian cysts or enlarged ovaries not due to PCOD; primary ovarian failure; sexual organ malformations or uterine fibroid tumors incompatible w/ pregnancy. Pregnancy & lactation.
Assess infertility & evaluate for hypothyroidism, adrenocortical deficiency, hyperprolactinemia, pituitary or hypothalamic tumors prior to treatment. Discontinue use if severe ovarian hyperstimulation syndrome (OHSS) occurs. Withhold hCG & refrain from coitus or use barrier contraceptives for at least 4 days if ovarian hyperstimulation occurs. Risk of OHSS, multiple pregnancies, pregnancy wastage, ectopic pregnancy, reproductive system neoplasms, congenital malformation. Personal or family history of thromboembolic events, severe obesity (BMI >30 kg/m2) or thrombophilia. Not to be used during pregnancy & lactation.
Sign Out
